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The transmembrane (TM) envelope protein of lentiviruses, including equine infectious anemia virus (EIAV),
is significantly larger than that of other retroviruses and may extend in the C-terminal direction 100 to 200
amino acids beyond the TM domain. This size difference suggests a lentivirus-specific function for the long
C-terminal extension. We have investigated the synthesis and processing of the EIAV TM protein by immune
precipitation and immunoblotting experiments, by using several envelope-specific peptide antisera. We show
that the TM protein in EIAV particles is cleaved by proteolysis to an N-terminal glycosylated 32- to
35-kilodalton (kDa) segment and a C-terminal nonglycosylated 20-kDa segment. The 20-kDa fragment was
isolated from virus fractionated by high-pressure liquid chromatography, and its N-terminal amino acid
sequence was determined for 13 residues. Together with the known nucleotide sequence, this fixes the cleavage
site at a His-Leu bond located 240 amino acids from the N terminus of the TM protein. Since the 32- to 35-kDa
fragment and the 20-kDa fragment are not detectable in infected cells, we assume that cleavage occurs in the
virus particle and that the viral protease may be responsible. We have also found that some cells producing a
tissue-culture-adapted strain of EIAV synthesize a truncated envelope precursor polyprotein. The point of
truncation differs slightly in the two cases we have observed but lies just downstream from the membrane-
spanning domain, close to the cleavage point described above. In one case, virus producing the truncated
envelope protein appeared to be much more infectious than virus producing the full-size protein, suggesting
that host cell factors can select for virus on the basis of the C-terminal domain of the TM protein.
Equine infectious anemia virus (EIAV) is a lentivirus,
related in genome organization (23, 36, 38), sequence (6, 23,
36, 38), and morphology (12) to the human immunodefi-
ciency virus (HIV), the cause of acquired immunodeficiency
syndrome. Depending on the host and the virus strain, an
EIAV-infected horse may (i) suffer a brief acute illness and
die, (ii) undergo multiple cycles of illness and recovery, or
(iii) remain clinically normal. Acute episodes involve fever,
viremia, weight loss, and leucopenia; and animals who have
multiple episodes become severely anemic and may show
central nervous system impairment. As with HIV, EIAV
persists even in clinically normal individuals, and blood cells
have been found to be infectious after disease-free intervals
of many years (7, 22). The principal target cell is a leukocyte,
probably the macrophage (22, 30, 31, 35).
Retrovirus transmembrane (TM) envelope proteins share
a number of common features (for a review, see reference 11
and E. Hunter and R. Swanstrom, Curr. Top. Microbiol.
Immunol., in press). They all have two highly hydrophobic
regions separated by a 110- to 160-amino-acid stretch that
contains at least two cysteine residues. One of these regions
is at or near the N terminus and is thought to play a role in
fusing the viral envelope with that of the host cell. The
second hydrophobic stretch is the presumptive membrane-
spanning region. Most retrovirus TM proteins, including
those of type B, C, and D viruses, as well as those of the
HTLV-I group, end within 50 amino acids downstream of
the TM domain. Most lentivirus TM proteins, on the other
hand, are considerably longer and may extend for more than
100 residues beyond the TM domain. In EIAV, this C-
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terminal region contains more than 200 amino acids. The
difference in length between the lentivirus TM proteins and
those of other retroviruses suggests a lentivirus-specific
function for the long C-terminal tail. As an initial step toward
defining a role for this protein segment in the viral life cycle
and/or pathogenesis, we studied the synthesis and process-
ing of the EIAV TM protein.
MATERIALS AND METHODS
Cells and virus. EIAV-producing cultures of equine fetal
kidney cells were grown in Eagle minimal essential medium
containing 15% fetal calf serum, 1% sodium pyruvate, and
nonessential amino acids. Uninfected and EIAV-infected
canine thymus (Cf2Th) cells were grown in Dulbecco mod-
ified Eagle medium containing 10% fetal calf serum. Cultures
of horse macrophages were established by seeding 6 x 108
buffy coat cells from fresh blood into a T150 plastic tissue
culture flask with 30 ml of RPMI 1640 containing 20% fetal
calf serum, 30% calf serum, and 1% sodium pyruvate.
Nonadherent cells were removed after 2 h, and Wyoming
strain virus was applied in the amount of 1.5 ml of viral stock
(containing 104.8 horse leukocyte infectious doses per ml)
per T150 flask. Cultures were maintained for up to 11 days,
by which time the infected cultures, but not the uninfected
controls, showed a marked cytopathic effect indicative of
EIAV infection. To isolate the virus, culture supernatants
were centrifuged at 200 x g for 4 min to remove cells and cell
debris, and the resulting supernatant was centrifuged at
100,000 x g for 90 min to pellet the virus.
Metabolic labeling. Cells were washed once in phosphate-
buffered saline and incubated for about 10 min at 37°C in
medium containing 10% dialyzed fetal calf serum but lacking
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methionine and cysteine. [35S]methionine and [35S]cysteine
(600 to 1,000 Ci/mmol; Amersham Corp.) were added to a
final level for each of 50 to 100 ,uCi/ml. For analysis of
cellular lysates, the incubation time was 2 h; for analysis of
viral particles, the incubation time was 5 h. Virus was
isolated as described above for the macrophage cultures.
Immune precipitation. Viral pellets or cells were lysed in
TNT buffer (20 mM Tris [pH 7.5], 200 mM NaCl, 1% Triton
X-100) containing 1 mM phenylmethylsulfonyl fluoride and
200 Kallikrein units of aprotinin per ml, and lysates were
centrifuged for 10 min at 10,000 x g in an Eppendorf
microfuge. Viral supernatants were incubated directly with
antisera and protein A-Sepharose (Pharmacia, Inc.). Cellular
supernatants were first boiled in 1% sodium dodecyl sulfate
(SDS)-1% 3-mercaptoethanol (,ME) before dilution with
TNT and incubation with antisera and protein A-Sepharose.
Immune precipitates were collected, washed in TNT, boiled
in gel loading dye, and applied to SDS-polyacrylamide gels.
For endoglycosidase F (endo F) digestion, a 30 RI sample of
a solution containing 0.05 M potassium phosphate (pH 6.8),
20 mM EDTA, 1% PME, 1% Triton X-100, and 0.2% SDS
was added to the washed immune precipitates; the suspen-
sions were boiled for 5 min; and 0.2 U of endo F (grade II;
Boehringer Mannheim Biochemicals) was then added to
each sample. They were incubated at 37°C for 4 h, where-
upon they were boiled in gel loading dye and applied to a gel.
Immunoblotting. The virus-containing pellet from an 8-day
culture of EIAV-infected horse macrophages was suspended
in 100 ,ul of gel loading dye and boiled. The high-speed pellet
from a mock-infected culture was treated identically. Sam-
ples of 15 ,ul per lane were fractionated on a 10- to 20%
SDS-polyacrylamide gel. After electrophoresis, the gel was
electroblotted onto an Immobilon membrane filter (Millipore
Corp.), and filter strips were subsequently incubated with
1:100 dilutions of antisera and then with 125I-protein A at 3 x
105 cpm/ml. Purified virus from equine kidney cells and from
canine thymus cells was also analyzed; each lane contained
about 25 ,ug of virus.
Infections and electroporation. A total of 105 uninfected
Cf2Th cells in a 60-mm (diameter) dish was incubated for 30
min in complete medium containing 20 ,ug of DEAE-dextran
per ml. This medium was then removed, and 0.5 ml of
virus-containing medium was applied and incubated for 30
min. Complete medium containing 5 p.g of Polybrene per ml
was then added. Cultures were propagated and analyzed for
virus production after several passes. The virus-containing
medium was taken from a confluent virus-producing culture
and was clarified and sterile filtered before use. For electro-
poration, 50 ,ug of DNA prepared as described previously
(35) was added to 106 Cf2Th cells in 1 ml of ice-cold
phosphate-buffered saline. The mixture was pulsed, allowed
to rest 10 min at 0°C, and diluted with 1 ml of complete
medium. After 10 min at room temperature, the mixture was
transferred to a T75 culture flask and propagated as usual.
Amplification of a portion of the env gene. Deoxyoligonu-
cleotides used in the amplification were 5'-GGATTCCTG
GATTGGGAGC-3' (bases 509 to 527 of the TM-protein-
coding sequence) and 5'-CAATTGTCAGAATACAAGC
AC-3' (complementary to bases 168 to 188 of the long
terminal repeat). A 0.5-,ug portion of cellular DNA was
mixed with 20 pmol of each oligonucleotide in 100 ,ul of
buffer containing 10 mM Tris hydrochloride (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2, 0.01% gelatin, 200 puM each all four
deoxynucleoside triphosphates, and 2.5 U of Thermus aqua-
ticus polymerase (Cetus-Perkin Elmer). The resulting mix-
ture was subjected to 35 cycles of denaturation (95°C for 1
min), annealing (50°C for 2 min), and extension (72°C for 10
min), by using the Ericomp thermal cycler. Amplification of
a 0.96-kilobase (kb) fragment was confirmed by electropho-
resis of a sample of the product. The remainder of the
reaction product was extracted with an equal volume of
chloroform, and DNA was precipitated by the addition of 2
volumes of ethanol. The suspended precipitate was digested
with the restriction endonucleases ApaI and SpeI, yielding a
0.47-kb fragment, which was purified by electrophoresis in a
1.2% gel of low-melting-point agarose. The ApaI and SpeI
sites follow bases 603 and 1071, respectively, of the TM-
protein-coding sequence. This fragment was cloned into
BlueScript-KS (Stratagene), which had been digested with
ApaI and SpeI. Individual white colonies were selected and
expanded, and minipreparations ofDNA were sequenced by
the dideoxy-chain termination method (37) by using the
Sequenase system and protocol (U.S. Biochemical Corp.).
The sequencing primer was 5'-GGCCCTCTGGAAAGTG
ACC-3' (bases 600 to 618 for the TM-protein-coding se-
quence).
Peptides and antisera. Three TM protein peptides were
synthesized, coupled, and administered to rabbits as de-
scribed previously (34). The sequence of peptide tm-1 is
Lys-Glu-Arg-Gln-Gln-Val-Glu-Glu-Thr-Phe-Asn-Leu-Ile-
Gly-Cys (residues 77 to 91 of the TM protein [2, 36]), and it
was coupled to keyhole limpet hemocyanin via its C-terminal
cysteine. Peptide tm-2 is Cys-Gly-Ser-Gly-Asp-Lys-Tyr-
Tyr-Lys-Gln-Lys-Tyr-Ser-Arg (residues 247 to 259 of the
TM protein), and peptide tm-3 is Cys-Leu-Asn-Pro-Gly-
Thr-Ser-His-Val-Ser-Met-Pro-Gln-Tyr-Val (residues 402 to
415). The N-terminal cysteines do not occur in the EIAV
sequence and were added to facilitate coupling.
Surface glycoprotein peptides were purchased in crude
form from Peninsula Laboratories. Peptide sgp-1 is Cys-
Ala-Glu-Ser-Lys-Glu-Ala-Arg-Asp-Gln-Glu-Met-Asn-Leu-
Lys-Glu (residues 41 to 55 of the mature protein [1, 29]), and
peptide sgp-2 is Cys-Leu-Pro-Ile-Ser-Ser-Glu-Ala-Asn-Thr-
Gly-Leu-Ile-Arg-His-Lys-Arg (residues 424 to 439). The
N-terminal cysteines of each were added to facilitate cou-
pling.
RESULTS
To investigate the EIAV env gene products, antisera to
five env peptides were raised (Fig. 1). Two of the peptides
are part of the surface glycoprotein (one near the N-terminus
and the other at the extreme C-terminus), and three are part
of the TM protein (one upstream of the putative membrane-
spanning region and two in the long C-terminal extension).
Rabbit antisera to these peptides were used in immune
precipitation and immunoblotting experiments with viral and
cellular lysates.
Identification of env gene products by immune precipitation.
Immune precipitation of radiolabeled viral proteins with the
surface glycoprotein antisera (anti-sgp-1 and anti-sgp-2) re-
vealed in SDS-polyacrylamide gel electrophoresis (PAGE)
analysis a single broad band corresponding to gp9O, as
described by Parekh et al. (33). The protein differs somewhat
in size in virus produced by cultured equine fetal kidney cells
(100 kilodaltons [kDa]; Fig. 2, lanes 4 and 9) and in virus
produced by EIAV-infected canine thymus cells (90 kDa;
lanes 2 and 7). Removal of carbohydrate side chains with
endo F resulted in the disappearance of the 90- and 100-kDa
species and the appearance (in both cases) of a 48-kDa
protein (lanes 3, 5, 8, and 10). This size agrees very well with
that predicted for the unglycosylated surface glycoprotein by
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FIG. 1. env gene of EIAV. N-termini of the mature surface
glycoprotein and of the TM protein have been determined by Ball et
al. (2). Short vertical bars represent potential N-linked glycosylation
sites. Black boxes represent peptides against which rabbit antisera
were raised. The dashed arrow immediately upstream of the tm-2
peptide indicates the cleavage site determined in this study. Abbre-
viations: H, putative membrane-spanning region; SA, splice accep-
tor found in tat-rev mRNA (8, 38a).
the nucleotide sequence (439 amino acids) (23, 36). Since the
48-kDa protein was produced by virus both from canine and
equine cells, the difference in the mature forms must result
from their pattern and/or extent of glycosylation and sialy-
lation. Thus, antisera to peptides near the N- and C-termini
of the predicted surface glycoprotein revealed a single
protein species of the expected molecular weight.
In contrast, antisera to peptides from the predicted TM
protein recognized more than one protein in lysates of
radiolabeled particles produced by cultured canine cells.
Whereas the TM sequence encodes 415 amino acids, antise-
rum to peptide tm-1 precipitated a species of average size,
a-sgp-2 a-sgp-1
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FIG. 2. Precipitation of the EIAV surface glycoprotein. Virus-
producing canine thymus cells (C) and equine kidney cells (E) as
well as uninfected canine cells (Un) were grown in [35S]methionine
and [35S]cysteine for 5 h. Virus was isolated by high-speed centrif-
ugation of the medium, and viral lysates were immune precipitated
with the indicated antiserum. Half of each sample from the infected
cells was then treated with endo F (+); the second half was
untreated (-). Samples were analyzed by SDS-PAGE. Molecular
masses (kilodaltons) of marker proteins are indicated to the right of
the gel.
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FIG. 3. Precipitation of viral lysates with TM protein antisera.
Virus-producing canine cells were labeled, virus was harvested, and
viral lysates were immune precipitated and treated with endo F (+)
or untreated (-), as described in the legend to Fig. 2. Lanes 1 and 5,
Immune precipitation was carried out in the presence of excess
competing peptide tm-i or tm-3, respectively. Lane 4, Whole
disrupted virus was treated with endo F, followed by immune
precipitation with anti-tm-1. Molecular masses (kilodaltons) of
marker proteins are indicated to the right of the gel.
only 32 kDa (Fig. 3, lane 2). Upon endo F treatment, the size
of this molecule was reduced to about 23 kDa (lane 3), which
is clearly too small to represent the entire coding region.
Antiserum to the C-terminal peptide tm-3, on the other hand,
did not precipitate the 32-kDa species but instead recognized
an unglycosylated molecule of about 20 kDa (lanes 6 and 7).
The simplest interpretation of these results is that the
415-residue TM protein undergoes cleavage to an upstream
gp32 portion and a downstream p20 segment. The 46-kDa
protein in lane 6 probably represents the uncleaved full-
length molecule, which, upon endo F treatment, was re-
duced to 40 kDa (lane 7). This interpretation is tentative,
however, since the putative full-length protein was not
recognized by anti-tm-1 (lane 2).
Essentially the same results were obtained with virus from
equine kidney cells. As with the surface glycoproteins (gp90
and gplOO), the upstream portion of the TM protein was
slightly larger in the equine cells (gp35) than in the canine
cells (gp32) (Fig. 4A, lanes 2 and 4), but endo F treatment
resulted in a 23-kDa protein in both cases (Fig. 4A, lanes 3
and 5). In addition, virus from the canine cells contained
(after digestion) a 22-kDa protein (C in Fig. 4A, lane 3), the
origin of which is documented below. As in the canine cells,
anti-tm-3 precipitated an unglycosylated p20 as well as the
putative full-length uncleaved TM protein (Fig. 4B, lanes 4
and 5). None of these proteins was detectable in uninfected
cells (Fig. 4A and B, lanes 1).
To confirm a viral origin for the observed proteins, we
used four additional antisera. Each of three antisera from
EIAV-infected horses precipitated not only the surface
glycoprotein but also gp32 and gp35 (Fig. 4A, lanes 7, 9, 11,
and 12). Like anti-tm-3, anti-tm-2 precipitated p20 from
canine and equine cells (Fig. 4B, lanes 7 and 8) but not from
uninfected cells (Fig. 4B, lane 6). Anti-tm-2 also recognized
the putative uncleaved gp48; its size, like those of gp90 and
gplOO and gp32 and gp35, appears to differ slightly between
the canine and equine cell viruses (Fig. 4B, lanes 2, 4, 7, and
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FIG. 4. gp35 and p20 in virus from canine and equine cells. Virus-producing canine cells (C) and equine kidney cells (E), as well as
uninfected canine cells (Un), were labeled, and virus was harvested and treated as described in the legend to Fig. 2. After immune
precipitation, samples were treated with endo F (+) or untreated (-). Horse sera 2 and 3 are from asymptomatic carriers of EIAV; horse
serum 1 is from an acutely infected horse. Arrows point to the mature TM proteins gp32 and gp35 (*) and to p249ag (panel A) and to the putative
full-length TM proteins gp46 and gp48 (*) and to p20 (panel B). Bands A and C in panel A, lane 3, are the mature TM protein and a shortened
form of the TM protein, respectively. Molecular masses (kilodaltons) of marker proteins are indicated to the right of each gel.
8). Thus, results with three peptide antisera and three horse
sera indicate that the EIAV TM protein exists in two
fragments in the virus, an upstream gp32 or gp35 and a
downstream p20.
Isolation and N-terminal sequencing of p20. The isolation
and purification by reversed-phase high-pressure liquid chro-
matography of EIAV gag proteins have been described
previously (18). Briefly, disrupted virus was fractionated in
an acetonitrile gradient and the fractions were assayed by
SDS-PAGE. Major peaks of optical density were analyzed
for the N-terminal sequence, and the viral origin of the
protein in question was confirmed by reference to the
nucleotide sequence (38). During the course of this work, a
protein of about 20 kDa was found and shown to have the
N-terminal sequence Leu-Ala-Gly-Val-Thr-Gly-Gf&-Ser-
Gly-Asp-Lys-Tyr-Tyr. Subsequently, the nucleotide se-
quence of the EIAV env gene was reported (36). It showed
that this protein begins 175 amino acids upstream of the C
terminus of the predicted env precursor protein, making it a
likely candidate for the p20 described above. This result is
completely consistent with the immune precipitation exper-
iments, which predict a cleavage site immediately upstream
of peptide tm-2. In the sequence given above, the third
glycine (underlined) is the N terminus of peptide tm-2, so
that cleavage occurred only six residues upstream. We
conclude that p20 predicted from the use of peptide antisera
in precipitation experiments can be identified in bulk prepa-
rations of purified virus.
The actual cleavage site predicted from the amino acid
sequence above together with the nucleotide sequence is
Ile-His/Leu-Ala. While not typical of sequences cleaved by
viral proteases, it is not so dissimilar that cleavage by a
cellular enzyme must be invoked. In particular, there is
precedent among the viral proteases for cleavage next to a
His residue, and branched amino acids such as Ile are often
observed at P2 and P2' sites (21).
Cleavage does not occur intracellularly. Examination of
cellular rather than viral lysates should reveal whether
cleavage to gp32 or gp35 and p20 occurs intracellularly or
after budding. In virus-producing equine kidney cells grown
for 2 h in 3"S-labeled precursors, we expect to detect the
newly synthesized envelope precursor (854 amino acids).
Since cleavage of this precursor to yield the surface glyco-
protein and the full-length TM protein is expected to be
accomplished by a cellular enzyme (by analogy to other
retroviruses), these two proteins should be detected as well.
The question is will gp35 and p20 be seen? Figure 5 shows
that they are not. Four env antisera precipitated the high-
molecular-weight glycosylated translational product of the
env gene, gPrefV, which, upon treatment with endo F, was
reduced in size to about 95 kDa, as expected. Anti-sgp-2 also
precipitated the mature surface glycoprotein gplO0, which
(as in Fig. 2, lane 5) was reduced to 48 kDa upon endo F
treatment (Fig. 5, lanes 1 and 2). Anti-tm-2 and anti-tm-3
precipitated the 48-kDa endo F-sensitive protein we presume
a-sgp-2+ am-1 .t-tm-2 +-tm-3
i r Is +
gPrenv a
gplO00 I 71}o _~ _ Moe-97
- 68
Uncleaved
Xb > - 43 tm protein?
_
-26
- 18
1 2 3 4 5 6 7 8
FIG. 5. gp35 and p20 are not detectable in lysates of infected
cells. Virus-producing equine kidney cells were grown for 2 h in
[35S]methionine and [35S]cysteine, lysed, boiled in 1% SDS and 1%
pME, and immune precipitated with the indicated antisera. Half of
each washed precipitate was treated with endo F (+); half was
untreated (-). Samples were analyzed by SDS-PAGE. Samples in
lanes 7 and 8 were analyzed on a different gel from those in lanes 1
to 6. gPrf', Envelope precursor. Molecular masses (kilodaltons) of
marker proteins are indicated on the right.
A
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FIG. 6. Detection of p20 in tissue-culture-adapted virus and in
virulent Wyoming strain virus by immunoblotting. (A) Purified virus
(about 25 jig per lane) from cultured equine (E) or canine (C) cells
was lysed, fractionated by SDS-PAGE, and blotted onto an Immo-
bilon membrane filter. Filter strips were incubated with the indi-
cated antiserum at a dilution of 1:100, washed, and then incubated
with 125I-protein A. (B) Primary cultures of horse monocyte-macro-
phages were infected (Inf) with Wyoming strain virus. Eight days
after infection, the cell supernatant was collected and virus was
pelleted by high-speed centrifugation. Viral lysates were treated as
described for panel A. Un, Lysate of high-speed pellet from cell
supernatant of uninfected cells. Molecular masses (kilodaltons) of
marker proteins are indicated beside each gel.
to be the full-length TM protein (Fig. 5, lanes 5 to 8).
However, neither anti-tm-1 (lane 3) nor natural horse serum
detected gp35, and neither anti-tm-2 nor anti-tm-3 precip-
itated p20 (lanes 5 and 7). We conclude that the cleavage
which gives rise to gp35 and p20 occurs later, perhaps in the
virus. We have tried to verify a viral cleavage by pulse-chase
experiments, but so little TM protein (either full length or
cleaved) is found in virus that the amount of radioactive
precursor needed for a very short labeling period is prohib-
itive.
Transmembrane protein cleavage also occurs in an EIAV
field strain. The experiments reported above were performed
exclusively with virus from cultured cells. Since such virus
is not pathogenic for horses, it clearly differs in important
ways from field strains. We therefore asked whether the TM
protein cleavage observed in tissue-culture-adapted virus
could also be observed in nonadapted pathogenic virus. To
accomplish this, we infected primary horse monocytes-
macrophages with Wyoming strain virus, cultured the in-
fected cells for up to 11 days, and pelleted virus from culture
supernatants. Since, in our hands, macrophage cultures have
proved difficult to radioactively label, viral lysates were
subjected to analysis by immunoblotting.
p20 from tissue-culture-adapted virus could be detected by
immunoblotting, by using either anti-tm-2 or anti-tm-3 (Fig.
6A, lanes 3 to 6), but gp32 and gp35 were not detectable with
anti-tm-1 (lanes 1 and 2) or with immune horse sera, except
after very long exposure. Viral lysates from the cultured
horse macrophages were therefore examined only with anti-
tm-2 and anti-tm-3. Both of these antisera recognized a
protein of 20 kDa that was not present in the uninfected
control (Fig. 6B). We conclude that the cleavage to gp32 or
gp35 and p20 is not a phenomenon restricted to nonpatho-
genic tissue-culture-adapted virus but occurs in Wyoming
strain virus in its presumptive natural target cell as well.
In summary, synthesis of the EIAV TM protein proceeds
in the following steps: (i) synthesis of the env precursor, (ii)
intracellular cleavage of the env precursor to yield the
surface glycoprotein gp9O or gplOO and the putative full-
length TM protein gp46 or gp48, and (iii) cleavage (possibly
viral) of gp46 or gp48 to the mature TM protein gp32 or gp35
and the C-terminal p20 fragment. p20 is found not only in
tissue-culture-adapted virus but also in virulent virus pro-
duced by infected horse macrophages.
A truncated env gene in some EIAV-producing cells. In this
section, we document a second phenomenon affecting the
EIAV TM protein: a genetic change that results in synthesis
of a shortened form of the protein in some cells. The normal
progenitor of the surface glycoprotein and the TM protein is
a 135-kDa glycosylated intracellular env precursor polypro-
tein which, upon endo F treatment, is reduced to about 95
kDa, as predicted by the nucleotide sequence. In at least one
case, however, a second env precursor appeared after con-
tinued passage of infected equine kidney cells. Examination
of 35S-labeled cellular lysates showed that the new form was
smaller (about 115 kDa) and was reduced to about 78 kDa
after endo F treatment (Fig. 7A, lanes 6 to 9). Since the
smaller precursor (Pr2) was precipitated by both surface
glycoprotein antisera and by anti-tm-1 and anti-tm-2 (lanes 1
to 4) but not by anti-tm-3 (lane 5), it appears to be truncated
at its C terminus relative to the full-size precursor Pr1. Since
it lacks about 18 kDa relative to Pr1 but was still recognized
by anti-tm-2, the truncation must have occurred immediately
downstream of peptide tm-2. Both forms of precursor were
synthesized by these cells. Virus-producing canine thymus
cells also synthesized two env precursors (Fig. 7B). In this
case, however, truncation must have occurred upstream of
peptide tm-2, since the shortened form is recognized by
anti-tm-1 (lane 5) but not by anti-tm-2 or anti-tm-3 (lanes 8
and 11).
Virus expressing the truncated env precursor is enriched
upon passage. We tested whether virus expressing the short-
ened env precursor is infectious. Virus from the parental
canine cell culture (which expresses both Pr1 and Pr2) was
applied to uninfected canine cells (generating culture II [Fig.
8A]). In addition, cellular DNA from the parental culture
was introduced into uninfected cells by electroporation
(generating culture I). After several weeks of passaging,
cultures I and II were grown in 35S-labeled amino acids, and
lysates were examined by immune precipitation. Both cul-
tures contained readily detectable truncated precursor (Pr2)
but little or no full-size precursor (Pr1) (Fig. 8B, lanes 2 and
4). Thus, upon passage to new cells, a significant enrichment
for the truncated env form occurred.
The enrichment process continued through a second
round. Virus from culture II was added to uninfected cells,
generating culture III, and DNA from culture II was intro-
duced into uninfected cells by electroporation, generating
culture IV. Subsequent immune precipitation revealed very
little Pr1 in culture III and no detectable Pr1 in culture IV
(Fig. 8B, lanes 6, 8, and 12). All of the env precursor in
culture IV was the same size as Pr2 of the parental culture
(lanes 7 to 10).
Two conclusions can be drawn from these results. First,
since the electroporated cultures I and IV contained only
Pr2, virus expressing only Pr2 must be infectious for canine
cells. Second, since passage of virus from the parental
culture to culture II and from culture II to culture III led to
enrichment of Pr2, virus expressing Pr2 must be more
infectious than virus expressing Pr1 and/or cells infected
with the Pr2 virus must have a growth advantage over those
infected with Pr1 virus.
Truncation is due to a genetic change. We hypothesized
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FIG. 7. Two sizes of envelope precursor protein. (A) Equine kidney cells. (B) Canine thymus cells. Virus-producing cells were grown in
35S-labeled amino acids for 2 h, lysed, boiled in 1% SDS and 1% OME, and immune precipitated with the indicated antiserum. Lanes: +,
samples treated with endo F after precipitation; -, untreated. Pr1 and Pr2 are the full-size and truncated precursors, respectively. Samples
in panel A, lanes 6 to 9, were not boiled before precipitation; samples in panel B, lanes 3, 6, 9, and 12, were uninfected; samples in lanes 10
to 12 were analyzed on a different gel from those in lanes 1 to 9. Molecular masses (kilodaltons) of marker proteins are indicated to the right
of each panel.
that Pr2 resulted from a mutant genome(s) containing either
a 3' deletion or a premature translation termination signal in
the env gene. Since Pr2 was recognized by anti-tm-1 but not
by anti-tm-2 or anti-tm-3 in the canine cells, such a mutation
presumably occurred upstream of the tm-2 peptide. To test
this theory, we amplified, subcloned, and sequenced a
portion of the env gene from the parental Cf2Th(EIAV)
culture and from culture II.
The sequences of 12 env subclones from the parental
culture revealed that four of them had in-frame termination
codons slightly upstream of peptide tm-2 (Fig. 9). Single-
base changes (relative to the prototype sequence [36]) at 11
other positions were also observed among the subclones, but
these did not result in termination signals. Thus, an open
reading frame was maintained in eight of the subclones.
These results are consistent with the synthesis of both Pr,
and Pr2 by cells of the parental culture.
Culture I
Uninfected Cells
Virus
Uninfected Cells
Culture II
Culture III
Virus s
Uninfected Cells
DNA II
Uniniected Cells
Culture IV
In contrast, 8 of 10 subclones from culture II had in-frame
terminators upstream of peptide tm-2. One additional sub-
clone terminated downstream of peptide tm-2 as a result of a
single-base deletion. Only 1 of the 10 maintained an open
frame in this region. These results account for the prepon-
derance of Pr2 synthesized by culture II. Thus, the truncated
env precursor results from premature termination codons in
the env gene. In 12 of the 13 cases we observed, these
terminators were located 7, 9, or 12 codons upstream of the
gp32-p20 cleavage site.
A truncated TM protein is detectable in virus. Cleavage
products expected from the full-size and truncated precur-
sors are shown in Fig. 10. Cleavage of Pr1 yields the surface
glycoprotein, the mature TM protein (gp32-35), and p20, as
documented in the preceding sections of this report. Cleav-
age of equine Pr2, which extends through peptide tm-2,
should also yield the mature TM protein (A in Fig. 10) as well
I II III P IV P IV
B --
1 2 3 4 5 6 7 8 9 10 11 12
200 -
97 - in SW lb =;;; "Aa Pr297-
~~~~~~~ito--
68-
43 -
26-
IL _
FIG. 8. Viral passage results in enrichment of the truncated precursor form. (A) Generation of new cultures of canine cells expressing
EIAV. (B) Immune precipitation of envelope precursors in the new cultures. The parental culture (P) and cultures I to IV were grown in
35S-labeled amino acids, lysed, and immune precipitated with anti-tm-1 (lanes 1 to 10) or horse serum with antibodies to EIAV (lanes 11 and
12). Lanes 1, 3, and 5, Precipitation carried out in the presence of excess peptide tm-1; +, endo F-treated after immune precipitation. Pr1 and
Pr2 are the full-length and truncated envelope precursors, respectively. Molecular masses (kilodaltons) of marker proteins are indicated to the
left of panel B.
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Leu Lys Lys Lys Phe His His Lys His Ala Ser Arg Glu Asp Thr Trp Asp Gln Ala Gln His Asn Ile His
CTG MG AAA AM TTC CAT CAC AM CAT GCA TCG CGA GM GAC ACC TGG GAC CAG GCC CM CAC MC ATA CAC
Parental (12) A2
Culture II (10)
A1 1Cf AJ T2
mG Aim
Deptide tm-2
Leu Ala Gly Val Thr Gly Gly Ser Gly Asp Lys Tyr Tyr Lys Gln Lys Tyr Ser Arg
CTA GCA GGC GTG ACC GGT GGA TCA GGG GAC AM TAC TAC MG CAG MG TAC TCC AGG
Parental (12)
Culture II (10)
A1 G1 C3
( )6
FIG. 9. Portion of the env gene sequence, along with its translation products, for the prototype EIAV strain (36). The sequence begins 20
residues downstream of the putative membrane-spanning region of the TM protein and continues through the peptide tm-2 region (residues
217 to 259 of the TM protein). Cellular DNAs from the parental Cf2Th(EIAV) culture and from culture II were amplified by using the
polymerase chain reaction, and amplified material was subcloned and sequenced. The number of subclones that were sequenced is given in
parentheses. Sequences were identical to the prototype except where indicated. Subscripts denote the number of clones with each change.
Boxes indicate that stop codons were created by the sequence changes. The dash denotes a deletion. The arrow indicates the cleavage site
between gp32 and p20.
as a short peptide (B in Fig. 10) that would nc
in immune precipitation experiments. Thus
altered products are expected in virus produc
cells expressing both precursor forms relal
expressing only Pr1. In virus produced by
canine culture, however, where Pr2 terminates
upstream of the gp32-p20 cleavage site, a shor
TM protein (C in Fig. 10) is expected. In
digestion of gp32 revealed a 22-kDa protein
lanes 3 and 8) in addition to the normal 23-kE
protein (Fig. 4A). Thus, absence of the lor
fragment did not prevent incorporation of the
protein into virus particles, and, as shown abo
ing virus is infectious.
Surface
Glycoprotein
Pr1
Pr2 (equine)
Pr2 (canine)
Mature
Tranamembrane
Protein
-/1V------
(A)
Intracellular
Cleavage
Viri
Cleav,
FIG. 10. Predicted cleavage products of the ob;
cursor proteins. Pr, is the full-size precursor; Pr2 i
form seen in canine cells and some equine cell
cleavage products of Pr2 include the mature TM prot
short peptides (B and C). tm-1, tm-2, and tm-3 are I
which antisera were raised. H, Very hydrophobic rn
presumptive membrane-spanning segment. Cleavage
nus of the surface glycoprotein is intracellular; cle
terminus of the mature TM protein may be viral.
At be detected
,- nn new nr
DISCUSSION
i'edvby-equine In general, EIAV strains capable of causing disease in
tive to those horses cannot be propagated in established tissue culture
the parental lines and will only replicate well in primary horse macro-
7 to 9 codons phages (24, 26). This is consistent with the observation that
tened formof the primary targets in vivo are cells of the monocyte-
fact, endo F macrophage lineage (24, 30, 31, 35). The commonly used
(C in Fig. 4 Malmquist variant of the virulent Wyoming strain was es-
)a mature TM tablished only after extended passaging in macrophages
ng C-terminal followed by successful infection of equine dermal or kidney
truncated TM cells (27, 29). This variant could subsequently be passed in a
yve, the result- variety of different equine cell lines as well as in feline and
canine cells (3), but it does not cause disease in horses.
Proviral DNA clones of this attenuated virus have been
completely sequenced (23, 36, 38), and gag and env proteins
have been isolated and partially or completely sequenced (2,
18). It is primarily this attenuated virus that has been
p2O examined in the present study.
Our first finding is that most (and perhaps all) of the
tm-2 tm-3 attenuated EIAV TM protein undergoes proteolytic process-
ing to yield a glycosylated membrane-spanning gp32 or gp35
and a C-terminal nonglycosylated p20. Processing also oc-
curs in equine macrophages infected in vitro with virulent
Wyoming strain virus. Therefore, the predominant form of
the mature TM protein in EIAV virus particles appears to be
gp32 or gp35 rather than the full-length translational product.
Indeed, we observed that some cells express a truncated env
gene and thereby synthesize only gp32 without the long
C-terminal region. Virus produced by such cells was highly
infectious for canine cells.
ai The processing that gives rise to gp32 or gp35 and p20
occurs about 45 residues downstream of the putative mem-
served env pre- brane-spanning region, at the sequence Ile-His/Leu-Ala.
is the truncated Since gp32 or gp35 and p20 were only detected in virus and
Is; presumptive not intracellularly, it is possible that processing is carried outLeptides against by the viral protease. The sequence at the cleavage site is not
egion thatis the inconsistent with this possibility, and we are currentlye
at the C termi- testing whether purified EIAV protease will cleave a syn-
avage at the C thetic peptide containing this sequence.
In HIV-1, most of the TM protein appears to be unproc-
GI C1
-0 IN
tm-l H I
mI/ m
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essed (41), though a small amount of a C-terminal peptide
was found in virus fractionated by high-pressure liquid
chromatography (17). C-terminal processing of other lentivi-
rus TM proteins has not been reported, but there are
precedents among the much shorter TM proteins in the
murine family of the type C retroviruses (13, 39). As with
EIAV, the role of this cleavage in the viral life cycle is
unknown and awaits mutagenesis experiments with infec-
tious molecular clones.
Our second finding is that some cells fail to express p20 at
all. In two different cell lines expressing attenuated virus, we
observed truncated forms of the envelope precursor poly-
protein. The point of truncation differed in the two instances,
but both occurred just slightly downstream of the putative
membrane-spanning region of the TM protein. In the case of
the equine fetal kidney cell line, the genome expressing the
truncated form was not infectious for equine dermal cells.
The reason for the lack of infectivity is unknown but may be
unrelated to a shortened envelope protein (for example,
truncation might have resulted from an insertion or deletion,
in which case the presumptive rev gene product would also
be altered). In the canine thymus cell line, however, virus
expressing the truncated form appeared to be much more
infectious for canine cells than was virus expressing the
full-size precursor. Infection of new cells, whether by expo-
sure to virus-containing culture media or by electroporation
of DNA, resulted in progressive enrichment of the short
form.
In the absence of an infectious molecular clone of EIAV,
we are unable to test whether the truncated envelope protein
and increased infectivity are causally related. However,
these results are very reminiscent of those seen with the
simian immunodeficiency virus (SIV). When propagated in
either cultured macaque lymphocytes or a rhesus monkey,
the TM protein of SIVmac has been found to be the full-
length 41-kDa form (19, 25, 32). When propagated in human
cells, however, rapid selection for a truncated form occurred
(4, 5, 19, 25, 32, 42). Truncation resulted from the appear-
ance of an in-frame termination codon immediately down-
stream of the membrane-spanning region (4, 5, 9, 16, 19, 20,
32). When virus expressing both the full-size and the trun-
cated envelope was introduced into macaque lymphocytes
or into a monkey, rapid selection for the full-size form
occurred (19, 25). Thus, depending on the host cell, the SIV
(and presumably EIAV) C-terminal extension of the TM
protein plays different roles. In some cells, it is not required
and even inhibits virus spread; but in cells of the animal in
which the virus causes disease, it is advantageous. Termi-
nation codons in the TM-protein-coding sequence have also
been found in some but not all isolates of HIV-2 (14, 28, 44)
and SIVagm (1, 10, 43).
The role of this region of the lentivirus in TM protein is
unknown. Indeed, we do not even know whether it plays a
role inside the infected cell during glycoprotein processing
and transport or during virus assembly, at the outside of an
uninfected cell during virus entry, or both. One approach to
this problem is to determine the location of p20 relative to
the viral membrane. There is a potential glycosylation site
midway through p20 that remains unmodified (endo F had no
effect on the size of the p20 fragment). This suggests that at
least the midregion of the molecule was confined to the
cytoplasmic side of the endoplasmic reticulum and hence is
inside the virus. Similarly, immune horse antisera do not
recognize p20-derived peptides (R. Montelaro, personal
communication), perhaps suggesting that p20 does not ap-
pear on the cell or viral surface. However, recent studies of
HIV-1 have suggested that its C-terminal region is at least
membrane associated (15) and possibly membrane spanning
(40). Thus, at least part of the region may be on the outside
of the virus (20, 40). R. Montelaro (personal communication)
has pointed out that the EIAV C-terminal region contains
structural features (such as an amphipathic helix) that resem-
ble those of HIV-1 (15, 40), suggesting that the orientation of
the EIAV TM protein is similar to that of HIV-1. Use of the
TM peptide antisera described in this report may help us
determine the locations of the various regions of the EIAV
protein.
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